Emerging literature, however, indicates other activities of PARP-1 that may explain the in vivo potency of some PARP-1 inhibitors that cannot be entirely attributed to their apparent in vitro activity and that could provide additional targets for anti-cancer therapies. Here, PARP1 is linked to cancer.